Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gurnell

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Pituitary|November 15, 2011
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literatureA K Annamalai, A F Dean, N Kandasamy, et al.
The EMBO Journal|August 26, 1998
A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormoneT N Collingwood, R Wagner, C H Matthews, et al.
Pituitary|May 24, 2022
<sup>11</sup>C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapyW A Bashari, M van der Meulen, J MacFarlane, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Pituitary|November 15, 2011
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literatureA K Annamalai, A F Dean, N Kandasamy, et al.
The EMBO Journal|August 26, 1998
A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormoneT N Collingwood, R Wagner, C H Matthews, et al.
Pituitary|May 24, 2022
<sup>11</sup>C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapyW A Bashari, M van der Meulen, J MacFarlane, et al.
Pageof 5